Home » News » 12/05 » Eli Lilly ups growth prediction

Eli Lilly ups growth prediction

Date published: 13/12/2005

Eli Lilly has told Wall Street investors that it is positioned to deliver sustained growth in 2006. The company announced that sales next year are expected to increase to more than $15 billion, coming from better performance from the drugs Zyprexa and Cymbalta.

Lilly president and chief operating officer Dr John Lechleiter said: "We are somewhat encouraged by Zyprexa's recent US performance where the erosion of Zyprexa prescriptions slowed in recent months.

"Our goals are to further stabilize US Zyprexa sales and sustain modest growth on a global basis." He also described that while there was an overall flat antidepressant market in 2005, Cymbalta has led all branded and promoted products in share-of-market growth during this period.

Cymbalta has also performed well in Europe and had the company's best ever anti-depressant launch in Germany. Lilly's chief executive Sidney Taurel told investors the company's situation was also buoyed by the fact there were no major drugs in line to lose their patent protection in the next five years and nine products launched since 2001 will produce increased revenue.

He added: "We continue to expand into new markets such as our recent submissions of Byetta in Europe for type 2 diabetes, Cialis in Japan for erectile dysfunction, and Cymbalta in key European markets."

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.